Direct Transdifferentiation of Non-Pluripotent Cells to Cardiomyocytes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mammalian heart lacks significant regenerative capacity, and existing methods for generating cardiac cells in vitro are inefficient and require the generation of pluripotent stem cells, which is a slower and riskier process.
Innovation Solution
A method involving the conversion of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate by increasing the quantity of reprogramming transcription factors such as Oct4, Klf4, Sox2, and Myc, and exposing the cells to lineage-specific differentiating factors like BMP4 and GSK-3 inhibitors to directly generate cardiomyocytes or other cell types without forming pluripotent intermediates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If reprogramming transcription factors (Oct4, Klf4, Sox2, Myc) are introduced to convert cells from one non-pluripotent fate to another, then cell fate conversion efficiency is improved, but there is a risk of forming pluripotent intermediates that may develop into teratomas
Solution Approach 1:
The patent applies partial reprogramming by introducing only specific transcription factors (Oct4, Klf4, Sox2, or Myc) for limited durations, rather than using all four factors continuously. This partial action achieves sufficient epigenetic remodeling for cell fate conversion while avoiding the complete pluripotent state that leads to teratoma formation. The conditional expression systems allow precise control over the extent and duration of reprogramming factor exposure.
Solution Approach 2:
The patent employs conditional expression systems that allow dynamic control of transcription factor expression levels and durations. By adjusting these parameters (expression timing, duration, and levels), the method optimizes cell fate conversion efficiency while minimizing the risk of pluripotent intermediate formation. Different parameter combinations can be used depending on the target cell type and desired outcome.
2Loss of time
If the method bypasses pluripotent stem cell generation to directly convert cells between non-pluripotent fates, then the time required for cell generation is reduced, but the process complexity increases due to multiple differentiation factors
Solution Approach 1:
The patent segments the cell fate conversion process into distinct phases: (1) reprogramming phase with transcription factors to induce epigenetic changes, (2) differentiation phase with lineage-specific factors to guide toward target cell fate. This segmentation allows optimization of each phase independently and simplifies the overall process by avoiding the intermediate pluripotent stage that would require separate maintenance and differentiation protocols.
Solution Approach 2:
The patent applies preliminary reprogramming action by introducing transcription factors that prepare the epigenetic landscape for subsequent differentiation. This preliminary action modifies chromatin accessibility and gene expression patterns in advance, making the cells more responsive to lineage-specific differentiation factors and reducing the total time required for complete cell fate conversion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for faster and safer generation of specific cell types like cardiomyocytes, bypassing the need for pluripotent stem cells and reducing the time required for cell fate conversion, while minimizing the formation of teratomas and maintaining the cells in a less differentiated state.
Implementation Method 1
increasing the quantity of at least one reprogramming transcription factor in a first non-pluripotent cell having a first non-pluripotent cell fate to generate a non-pluripotent intermediate cell
Implementation Method 2
The development or growth of pluripotent cells is limited, e.g., by limiting the expression of, or contact of the cells to, the reprogramming transcription factor(s), or by contacting the cell that differentiates in response to lineage-specific differentiating factors with an inhibitor that inhibits the growth of pluripotent cells. The inhibitor that inhibits the growth of pluripotent cells is a JAK inhibitor.
Data Source
Figure 1a~1d
Figure 2a~2d
Figure 3a~3e
AI summary
The present invention generally provides methods and compositions for transdifferentiation of an animal cell from a first non-pluripotent cell fate to a second non-pluripotent cell fate. Also provided are methods and compositions for the transdifferentiation of an animal cell from a non-pluripotent mesodermal, endodermal, or ectodermal cell fate to a different non-pluripotent mesodermal, endodermal, or ectodermal cell fate.